A Phase III Randomized, Double-Blind, Placebo Controlled, Multi-centre Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative

Administered By

Awarded By

Contributors

Start/End

  • December 19, 2019 - December 19, 2024